|
1
|
Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
|
J Clin Oncol
|
2006
|
2.57
|
|
2
|
MicroRNAs in colorectal cancer: translation of molecular biology into clinical application.
|
Mol Cancer
|
2009
|
2.45
|
|
3
|
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma.
|
J Transl Med
|
2012
|
1.62
|
|
4
|
MicroRNA involvement in glioblastoma pathogenesis.
|
Biochem Biophys Res Commun
|
2009
|
1.45
|
|
5
|
Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.
|
J Exp Clin Cancer Res
|
2010
|
1.36
|
|
6
|
Identification and functional screening of microRNAs highly deregulated in colorectal cancer.
|
J Cell Mol Med
|
2012
|
1.34
|
|
7
|
MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
|
Cancer Sci
|
2011
|
1.28
|
|
8
|
Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients.
|
Genes Chromosomes Cancer
|
2012
|
1.26
|
|
9
|
Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer.
|
J Cell Mol Med
|
2012
|
1.24
|
|
10
|
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
|
Radiat Oncol
|
2012
|
1.16
|
|
11
|
Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer.
|
World J Gastroenterol
|
2012
|
1.14
|
|
12
|
MiR-34b is associated with clinical outcome in triple-negative breast cancer patients.
|
Diagn Pathol
|
2012
|
1.11
|
|
13
|
MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.
|
Tumour Biol
|
2012
|
1.08
|
|
14
|
MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications.
|
J Cell Mol Med
|
2011
|
1.02
|
|
15
|
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
|
Med Oncol
|
2012
|
1.00
|
|
16
|
Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer.
|
Cancer Biomark
|
2012
|
0.98
|
|
17
|
Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.
|
Breast Cancer Res
|
2008
|
0.92
|
|
18
|
Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells.
|
Int J Colorectal Dis
|
2012
|
0.90
|
|
19
|
Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the Central European population.
|
Eur J Med Res
|
2012
|
0.88
|
|
20
|
Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.
|
Cardiovasc Toxicol
|
2012
|
0.87
|
|
21
|
Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
|
Int J Oncol
|
2012
|
0.84
|
|
22
|
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
|
BMC Gastroenterol
|
2014
|
0.83
|
|
23
|
Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
|
Cancer Biother Radiopharm
|
2010
|
0.83
|
|
24
|
Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.
|
Wien Klin Wochenschr
|
2010
|
0.82
|
|
25
|
Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artifacts in serum obtained from clot activator-containing collection devices.
|
Clin Chem
|
2006
|
0.81
|
|
26
|
Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer.
|
Nutr Cancer
|
2013
|
0.79
|
|
27
|
Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.
|
Med Oncol
|
2012
|
0.78
|
|
28
|
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
|
BMC Cancer
|
2014
|
0.77
|
|
29
|
Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry.
|
BMC Public Health
|
2012
|
0.76
|
|
30
|
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
|
Future Oncol
|
2015
|
0.75
|
|
31
|
Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.
|
Anticancer Res
|
2014
|
0.75
|
|
32
|
[A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
|
Klin Onkol
|
2008
|
0.75
|
|
33
|
[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
|
Klin Onkol
|
2009
|
0.75
|
|
34
|
DIOS - database of formalized chemotherapeutic regimens.
|
Stud Health Technol Inform
|
2013
|
0.75
|
|
35
|
[Clinical aspects of trastuzumab treatment in breast cancer].
|
Klin Onkol
|
2009
|
0.75
|